


506
NA
81:1

DISPLAY

JANUARY 1984
VOLUME 81
NUMBER 1

LIBRARY
FEB 1984
UNIVERSITY OF
WASHINGTON



NATURAL SCIENCES

Proceedings OF THE National Academy of Sciences

OF THE UNITED STATES OF AMERICA

BIOLOGICAL SCIENCES

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

Proceedings OF THE National Academy of Sciences

OF THE UNITED STATES OF AMERICA

Officers of the Academy

FRANK PRESS, *President*
JAMES D. EBERT, *Vice President*
BRYCE CRAWFORD, JR., *Home Secretary*
WALTER A. ROSENBLITH, *Foreign Secretary*
ELKAN R. BLOUT, *Treasurer*

Editorial Board of the Proceedings

| | | |
|-------------------|--|----------------------|
| ROBERT A. ALBERTY | DANIEL E. KOSHLAND, JR., <i>Chairman</i> | |
| K. FRANK AUSTEN | PETER D. LAX | J. EDWIN SEEGMILLER |
| PAUL BERG | ROBERT E. MARSHAK | ROBERT L. SINSHEIMER |
| JOHN R. BORCHERT | PETER H. RAVEN | CHARLES H. TOWNES |
| JOHN E. DOWLING | JOHN RODGERS | FRANK H. WESTHEIMER |
| | NEVIN S. SCRIMSHAW | JAMES B. WYNGAARDEN |

Managing Editor: FRANCES R. ZWANZIG
Senior Associate Editor: GARY T. COCKS
Associate Editor: CAY BUTLER
Associate Editor: TERRY W. PEARSON
Associate Editor: DOROTHY P. SMITH
Assistant Managing Editor: JOANNE D'AMICO

Senior Copy Editor: LYNN A. BROWN
Copy Editors: BARBARA A. BACON, MARYANNE CUNNINGHAM-AGNEW, RUTH E. ESCH,
P. J. GROFF, JANET L. OVERTON, ERIC R. WASSYNG
Administrative Assistants: DELORES BANKS, JACQUELINE BODE, BEULAH EDWARDS,
CYNDY MATHEWS
Circulation: JULIA LITTLE, VIRGINIA TREADWAY

Editorial correspondence: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 2101 Constitution Avenue, Washington, DC 20418.

Business correspondence: Circulation Office of the PROCEEDINGS, National Academy of Sciences, 2101 Constitution Avenue, Washington, DC 20418.

Information for Contributors: See issue Number 1, January 1984.

Copyright: The National Academy of Sciences has copyrighted this journal as a collective work and does not own copyrights for individual articles. Requests for permission to reproduce parts of individual articles or for reprints of individual articles should be addressed to the authors. Microforms of complete volumes are available to regular subscribers only and may be obtained from University Microfilms, Xerox Corporation, Ann Arbor, MI 48103.

Subscriptions: All correspondence concerning subscriptions should be addressed to the Circulation Office of the PROCEEDINGS. Subscriptions are entered on a calendar year basis only. For 1984, subscription rates are \$185 in the United States and \$220 elsewhere. Subscribers are requested to notify the Circulation Office of the PROCEEDINGS 6 weeks in advance of any change of address; also the local postmaster. The Academy is not responsible for nonreceipt of issues because of an improper address unless a change of address is on file. The notice of address change should list both the old and new addresses. Claims for replacement copies will not be honored more than 60 days after the issue date for domestic subscribers and not more than 90 days after the issue date for foreign subscribers.

Back Issues: Volumes 76-81, January 1979 and thereafter, are available from the Circulation Office of the PROCEEDINGS. The price of a single issue is \$21.00 for Volumes 76-78 or \$11.00 for Volumes 79-81.

Second class postage paid at Washington, DC, and at additional mailing offices.

PRINTED IN THE USA

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (ISSN-0027-8424) is published semimonthly by THE NATIONAL ACADEMY OF SCIENCES, 2101 Constitution Avenue, Washington, DC 20418.

© 1984 by THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.

POSTMASTER: Send address changes to: PROCEEDINGS, 2101 Constitution Ave., Washington, DC 20418.

Human anti-idiotypic antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?

(internal image of antigen/gastrointestinal cancer/monoclonal antibody)

HILARY KOPROWSKI*, DOROTHEE HERLYN*, MICHAEL LUBECK*, ELAINE DEFREITAS*, AND HENRY F. SEARS†

*The Wistar Institute, 36th and Spruce Streets, Philadelphia, PA 19104; and †American Oncologic Hospital, Fox Chase Cancer Center, Central and Shellmire Avenues, Philadelphia, PA 19111

Communicated by John R. Brobeck, August 31, 1983

ABSTRACT Inoculation of human subjects with mouse monoclonal antibody results in the production of anti-idiotypic antibody that reacts with the binding site of the monoclonal antibody. This reaction is hapten-inhibited, suggesting that an internal image of the antigen is produced by the anti-idiotypic response. The anti-idiotypic antibody isolated from sera of three patients showed significant crossreactivity. Patients who developed the anti-idiotypic antibody improved clinically and had long remission from their disease. The possible presence of the internal image of cancer antigen on the human immunoglobulin molecule may change the conditions under which the immune system reacts to the tumor antigen and may open new approaches to the control of tumor growth.

The treatment of human leukemias with mouse monoclonal antibody (mAb) directed against antigen(s) present on leukemia cells results in a transient destruction of the leukemia cells (1), observed almost immediately after administration of the mAb (2). Sera of some patients who received anti-Leu 1 mAb for treatment of T-cell leukemia inhibited binding of fluoresceinated mAb to T leukemia cells and were considered to contain an anti-idiotypic (anti-Id) antibody. This was also observed in sera of renal transplant patients who received an OKT3 anti-T-cell mouse mAb (3). It has been suggested that binding of anti-Id to the mAb may prevent the antitumor activity of the mAb (1). This may be true in cases when direct action of mAb on cancer cells occurs (2). However, when no immediate antitumor effect of mAb is observed and when induction of tumor cell destruction occurs only a long time after the administration of mAb (4), it may be that an immune response of the host to his tumor is induced by mAb treatment.

Jerne has postulated a network of interacting antibody molecules and lymphocytes in the immune system in which idiotypes of antibody molecules are recognized by anti-idiotypic antibodies and cells (5). Within the set of anti-idiotypic antibodies could be expected to be those that were directly complementary to the paratope—i.e., the antigen binding site of the idiotypic antibody. The binding of such anti-idiotypic antibodies to the idiotypes has in fact been shown to be inhibitable by the antigen. This has led to the concept that such anti-idiotypic antibodies are internal images of the antigen. It was therefore predicted that priming an animal with anti-Id rather than with an antigen would be possible, and this, in fact, has been successfully achieved (6). The first physiological evidence that anti-Id could mimic the action of an antigen was obtained with anti-Ids against insulin (7). Direct evidence for the beneficial effect of an anti-Id antibody in infectious diseases has recently been found in mice primed with anti-Id in the absence of antigen that appeared immunized against *Trypanosoma rhodesiense* after such treatment

(8). When these animals were challenged with *T. rhodesiense*, specific idio type appeared in all animals, some of which had the specific idio type even before challenge.

In the present paper, we describe the development of anti-Id in sera of patients with gastrointestinal cancer who were treated with mouse mAb. Furthermore, we show that binding between the anti-Id and mAb can be inhibited by hapten. This suggests that the anti-Id is the internal image of the antigen expressed by the cancer cells. Finally, we discuss these findings in relation to the outcome of mAb treatment of gastrointestinal cancer.

MATERIALS AND METHODS

mAbs. Mouse mAbs 17-1A, C₄2032, and C₄1472, which bind to human gastrointestinal cancer cells, have been described elsewhere (9, 10). mAb C₄2032 is specific for colorectal carcinoma (CRC)-associated antigen(s) of M_r 180,000, 160,000, 50,000, and 40,000. mAb C₄1472 (IgG2a) is specific for a CRC-associated antigen of M_r 50,000. The A5C3 mAb against hepatitis virus has been described (11). mAb 17-1A (IgG2a, κ light chain) and C₄2032 (IgG2a, κ light chain) were purified from ascites obtained from hybridoma-bearing mice by affinity chromatography on a protein A-Sepharose column (Pharmacia) as described by Ey *et al.* (12).

Colorectal Cancer Extract. The 3 M KCl extract of SW-1222 cells, a cell line derived from colorectal cancer, has been described (13). Since this preparation binds mAb 17-1A, it seems likely that the material containing the antigen is in soluble form.

Patients. All patients had metastatic or recurrent gastrointestinal adenocarcinoma and were injected systemically with one dose of a purified sterile pyrogen-free preparation of mAb 17-1A (9) concentrated from ascites fluid of BALB/c mice (14). Of 9 patients who received 192 mg or less of mAb, 7 developed anti-mouse globulin antibodies (10). Of 20 patients who received 200–1,000 mg of mAb, 3 developed anti-mouse globulin antibodies (10). Sera of 3 patients of the first group who developed anti-mouse globulin antibodies (nos. 07, 08, and 09) (10) and of 2 patients of the second group (nos. 14 and 23) were either screened or processed for isolation of anti-Id antibodies. Sera used for isolation of anti-Id antibodies from subjects 07, 08, and 23 were obtained at the time when all 3 showed the highest concentration of anti-mouse globulin antibodies (see Fig. 1). Patient 08 received a second injection of 130 mg of mAb 20 months after the first injection, and serum obtained after this second injection was used in a screening test for the presence of anti-Id (Table 1).

Preparation of Rabbit Anti-Idiotypic Antibodies. New Zealand White rabbits were injected subcutaneously at multiple sites with 300 μ g of purified mAb 17-1A emulsified in Freund's complete adjuvant and, 30 days later, were injected intramuscularly with 100 μ g of mAb 17-1A. Sera were col-

The publication costs of this article were defrayed in part by page charge

lected on day 10 of the secondary response. Antisera were adsorbed on mAb C₄2032 and on mAb 17-1A immunoadsorbents as described below.

Isolation of Anti-Idiotypic Antibodies from Human Sera. Immunoadsorbents were prepared by coupling purified mAbs (30 mg each) to 2 ml of Affi-Gel 10 (Bio-Rad). Sera were obtained from patients injected with one dose of mAb 17-1A (10, 14). Serum samples previously shown by radioimmunoassay to contain anti-murine IgG antibody were sequentially adsorbed on mAb C₄2032 and 17-1A immunoadsorbents to remove anti-isotypic and anti-idiotypic antibodies, respectively. Adsorbed antibodies were eluted with 0.1 M glycine buffer (pH 2.8), immediately neutralized with phosphate buffer, and dialyzed against phosphate-buffered saline; the protein was quantitated by absorption at 280 nm ($A_{280}^{1\%} = 14$).

Competition Assay for Detection of Anti-Id. Polystyrene beads (0.25 in, 6.35 mm) (Precision Plastic Ball, Chicago; Lot C-2084) were washed three times with 95% ethanol. The air-dried beads were incubated overnight at 4°C with gentle shaking with a dilution of either rabbit or human anti-Id antibody in 0.02 M sodium tetraborate (pH 8.2), then washed three times with phosphate-buffered saline and further incubated for at least 3 hr at room temperature with phosphate-buffered saline/2% bovine serum albumin/0.04% NaN₃. The beads were then exposed to ¹²⁵I-labeled mAb 17-1A as the reference idotype and incubated with the potential source of human anti-Id—i.e., human sera diluted to 25% concentration in Ca²⁺-, Mg²⁺-free phosphate-buffered saline/2% bovine serum albumin/0.04% NaN₃. After an additional overnight incubation, the beads were washed and the radioactivity bound was measured in a gamma counter.

Stimulation of Peripheral Blood Mononuclear Cells. Peripheral blood mononuclear cells were stimulated with F(ab')₂ fragments at 10 ng/ml of mAb 17-1A *in vitro* as described (15) to activate antigen-specific T cells. During the following 7 days, aliquots of cells were separated into T- and B-cell populations by rosetting with sheep erythrocytes treated with 2-aminoethylisouronium bromide (16). Both populations were stained with F(ab')₂ fragments of mAb 17-1A or anti-influenza mAb and goat anti-mouse fluorescein-conjugated Ig and subsequently analyzed in a cytofluorograph. In addition, peripheral blood mononuclear cells from the same patient were stimulated with F(ab')₂ fragments of mAb 17-1A or anti-influenza mAb for 9 days in a modified Mishell-Dutton culture for specific human Ig production (15). Supernatants from these cultures were assayed in a solid-phase enzyme-linked immunosorbent assay for specific human IgG (KPL Laboratories, Gaithersburg, MD).

RESULTS

To screen serum samples for the presence of anti-Id, a competition assay was performed using rabbit anti-Id and four human sera previously incubated with ¹²⁵I-labeled mAb 17-1A. The results (Table 1) indicate that the three sera (nos. 23, 09, and 14) obtained after one injection of mAb showed inhibition of binding of mAb 17-1A that was higher than that of pre-mAb injection serum of patient 14 were low as compared with those of the other two sera but higher than for the pre-mAb exposure serum of the same subject. Inhibition values for serum obtained from patient 08, 7 days after he received a *second* injection of mAb were already high. This crude rapid screening assay with polyclonal rabbit anti-Id serum was followed by isolation and purification of individual anti-Ids by the immunoadsorbent technique described in *Materials and Methods*. Anti-Ids isolated from serum of subject 23, who received 750 mg of mAb, and from sera of

Table 1. Inhibition of binding of ¹²⁵I-labeled mAb 17-1A to rabbit anti-Id 17-1A by patients' sera

| Serum no. | Days after mAb injection | % inhibition of binding of ¹²⁵ I-labeled 17-1A to rabbit anti-Id 17-1A | | |
|-----------|--------------------------|---|-----|-----|
| | | 10% | 25% | 50% |
| 23 | 0* | 0 | 21 | 2 |
| | 108 | 25 | 96 | 73 |
| | 184 | 17 | NT | 87 |
| 09 | 0* | NT | 20 | NT |
| | 28 | NT | 46 | NT |
| 14 | 0 | 0 | NT | 0 |
| | 49 | 10 | NT | 17 |
| 08 | 0* | 0 | 21 | NT |
| | 7† | 31 | 64 | NT |

Rabbit anti-Id 17-1A (7.5 μg/ml) was coupled to polystyrene beads. ¹²⁵I-labeled 17-1A (12,500 cpm) was first incubated on ice with 10%, 25%, or 50% serum for 1 hr and then added to the coupled beads. Percentage of inhibition of binding of ¹²⁵I-labeled 17-1A to rabbit anti-Id 17-1A was calculated by the following formula: % binding inhibition = 100 - [(100 × cpm bound in presence of serum)/cpm bound without serum]. NT, not tested.

*Sample obtained immediately before mAb injection.

†Serum obtained 7 days after second administration of mAb.

indicated in Fig. 1), were shown to be human immunoglobulins by binding to ¹²⁵I-labeled anti-human F(ab')₂ fragments. The yield of anti-Id protein from serum samples varied: from no. 08, 13 μg/ml; from no. 07, 8.9 μg/ml; from no. 23, 43 μg/ml. The largest amount was obtained from no. 23,




FIG. 1. Presence of human anti-mouse globulin antibody in sera of three subjects as determined by binding to mouse mAb 17-1A in the presence of ¹²⁵I-labeled rabbit anti-human F(ab')₂ immunoglobulin (14). Dotted arrows indicate days after treatment when serum samples used for isolation of anti-idiotypic antibody were taken (one sample from patient 23, pooled sera from patients 07 and 08). Solid

Table 2. Binding of human anti-idiotypic 17-1A antibodies to monoclonal antibodies

| Patient | Anti-Id, $\mu\text{g/ml}$ | Binding of ^{125}I -labeled mAb to anti-Id, cpm | | | |
|---------|------------------------------|--|---------------------|---------------------|---------------|
| | | 17-1A | C ₄ 2032 | C ₄ 1472 | A5C3 |
| 08 | <5.0 | 1,693 \pm 131 | 214 \pm 31 | 308 \pm 44 | 166 \pm 18 |
| 07 | 6 | 1,023 \pm 91 | 168 \pm 26 | 363 \pm 21 | 251 \pm 29 |
| 23 | 18 | 21,339 \pm 156 | 427 \pm 24 | 512 \pm 59 | 813 \pm 101 |
| | 7 | 7,956 \pm 293 | 208 \pm 15 | NT | 427 \pm 23 |

cpm bound to normal human IgG (40 $\mu\text{g/ml}$) of ^{125}I -labeled 17-1A, C₄2032, and A5C3 were 151 \pm 25, 139 \pm 32, and 247 \pm 32, respectively. Results represent mean \pm SD of triplicate determinations. NT, not tested.

which also showed the highest levels of anti-mouse globulin antibodies (Fig. 1).

Binding of the isolated anti-Id to mAb 17-1A and to three other mAbs is shown in Table 2. The results indicate that the binding of anti-Ids from all three sera to mAb 17-1A was significantly higher than to the three other mAbs, two of which (C₄2032 and C₄1472) also detect antigenic sites on CRC cells, though these sites are different from those recognized by mAb 17-1A (10). Immunoglobulin isolated from sera of all three subjects prior to exposure to mAb 17-1A was adjusted to approximately 2.5 $\mu\text{g/ml}$ and coupled to polystyrene beads. These preparations did not bind any of the mAbs listed in Table 1, indicating the absence of anti-Id in pre-exposure serum.

These results indicate that anti-Id could be detected by the screening assay in four sera of patients injected with mouse mAb and that anti-Id could be isolated and purified from three sera reacting only with the idiotype injected into the patient.

Crossreactivity Between Human Anti-Ids. The results of the competition assay (Table 3) indicate significant crossreactivity between the anti-Ids of sera of patients 07 and 23 and slightly less but still significant crossreactivity between anti-Id sera of patients 08 and 23. Similar crossreactivity was found between anti-Id 07 and post-mAb serum obtained from no. 08 (results not shown). These results suggest that the anti-Ids in different patients are directed against the same site.

Is the Anti-Id Directed to the Framework or Antigenic Site of the Idiotype Determinants? To answer this question, ^{125}I -labeled mAb 17-1A was incubated with a 3 M KCl cell extract of a human colon carcinoma that binds mAb 17-1A and with 3 M KCl extract of melanoma cells that does not bind mAb 17-1A. The antibody-antigen mixture was then added to no. 23 anti-Id-coated beads and binding was compared with binding of the radiolabeled mAb alone. These experiments were performed with nonsaturating amounts of iodinated mAb to detect changes in binding with small amounts of competitive haptens. For control purposes, the iodinated mAb 17-1A was mixed with an extract from melanoma cells that had previously been shown to not bind mAb 17-1A. The CRC cell extracts in concentrations of 0.1 or 0.5 mg/ml were found to inhibit the binding of anti-Id to iodinated mAb 17-1A by 39% and 68%, respectively, whereas the extract from melanoma cells in concentrations up to 0.5 mg of protein/ml

did not significantly affect mAb binding (Table 4). This hapten inhibition of the binding reaction suggests the presence of an "internal image" of the CRC epitope on the anti-Id molecule, as supported by the finding that the 3 M KCl extract of CRC cells did not bind to the anti-Id but did bind, as expected, to mAb 17-1A.

Stimulation of B Cells by mAb 17-1A. Buffy coat cells were obtained from patient 23, 5 months after injection of mAb, and from patient 08, 20 months after injection of mAb. The percentage of lymphocytes that specifically bound 17-1A F(ab')₂ of patient 08 was 1.2 and that of patient 23 was 0.2. During 7 days in culture with mAb 17-1A, the percentage of lymphocytes of patient 23 that specifically bound 17-1A F(ab')₂ increased from 0.2 to 13. All the 17-1A-binding cells were present in the B-cell population. In addition, after 9 days, human anti-17-1A mAb IgG was detected. Incubation of lymphocytes from the same patient with anti-influenza mAb under identical conditions produced no detectable human Ig to either mAb 17-1A or anti-influenza mAb.

Patients Who Responded with a Remission After mAb Treatment. Table 5 gives data on five patients, four of whom had a small to medium tumor burden of metastatic or recurrent colorectal adenocarcinoma (14) and one, no. 14, who had a pancreatic carcinoma with small liver metastases. The tumors in all five patients regressed after a single administration of mAb 17-1A. Anti-Id was detected in the sera of four patients in the screening test, and the anti-Id was isolated and purified from sera of three other patients. Three patients (nos. 07, 09, and 14) are currently without evidence of tumor growth. Patient 08 had a local recurrence of tumor 18 months after mAb 17-1A treatment without any additional therapeutic measures. It is too soon to evaluate the long-term therapeutic results in patient 23.

DISCUSSION

mAb 17-1A has been used successfully to diagnose gastrointestinal cancers in humans by binding to tumor tissue *in situ*

Table 4. Hapten inhibition of binding of human anti-Id to mAb 17-1A

| Source | Hapten | | % inhibition of binding of anti-Id 23 to ^{125}I -labeled 17-1A |
|---------------|-----------------|--|--|
| | Conc., mg/ml | | |
| CRC SW-1222 | 0.5 | | 68.5 |
| | 0.1 | | 39.4 |
| MEL SK-MEL-21 | 0.5 | | 6.6 |
| | 0.1 | | 0 |

CRC = colorectal cancer tissue culture line. MEL = melanoma tissue culture line. ^{125}I -Labeled mAb 17-1A was mixed with 3 M KCl cell extracts to final extract concentrations of 0.5 and 0.10 mg/ml and 62,500 cpm of iodinated mAb per ml. After a 1-hr incubation on ice, 200 μl of the mixture or 200 μl of iodinated mAb alone was added per polystyrene bead coupled with anti-Id 17-1A (15 $\mu\text{g/ml}$;

Table 3. Crossreactivity between human anti-Ids in competition assay for detection of anti-Id

| Antibody | First | | cpm bound | % inhibition of mAb 17-1A binding |
|------------|------------|--|-----------|-----------------------------------|
| | Second | | | |
| Anti-Id 23 | None | | 4,297 | 0 |
| | 07 Pre-mAb | | 4,595 | |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.